Mimedx (MDXG) Cash from Operations Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.93% |
| Dec 31, 2025 | 34.68% |
| Sep 30, 2025 | 52.88% |
| Jun 30, 2025 | 46.10% |
| Mar 31, 2025 | 19.45% |
| Dec 31, 2024 | 23.32% |
| Sep 30, 2024 | 51.25% |
| Jun 30, 2024 | 60.58% |
| Mar 31, 2024 | 19.05% |
| Dec 31, 2023 | 46.23% |
| Sep 30, 2023 | 30.37% |
| Jun 30, 2023 | -17.78% |
| Mar 31, 2023 | -19.11% |
| Dec 31, 2022 | -27.10% |
| Sep 30, 2022 | -44.34% |
| Jun 30, 2022 | -17.32% |
| Mar 31, 2022 | -24.25% |
| Dec 31, 2021 | -22.48% |
| Sep 30, 2021 | 17.34% |
| Jun 30, 2021 | -26.15% |
| Mar 31, 2021 | -46.88% |
| Dec 31, 2020 | -34.23% |
| Sep 30, 2020 | -21.35% |
| Jun 30, 2020 | -25.03% |
| Mar 31, 2020 | -37.51% |
| Dec 31, 2019 | -36.80% |
| Sep 30, 2019 | -18.67% |
| Jun 30, 2019 | 12.54% |
| Mar 31, 2019 | -56.76% |
| Dec 31, 2018 | 12.78% |
| Sep 30, 2018 | 14.46% |
| Jun 30, 2018 | 96.62% |
| Mar 31, 2018 | 46.94% |
| Dec 31, 2017 | 91.80% |
| Sep 30, 2017 | 86.92% |
| Jun 30, 2017 | 114.47% |
| Mar 31, 2017 | 59.31% |
| Dec 31, 2016 | 61.18% |
| Sep 30, 2016 | 35.76% |
| Jun 30, 2016 | 40.21% |
| Mar 31, 2016 | 11.40% |